Author

Margaret B. Ferguson

Observed names: Margaret B Ferguson, Margaret Ferguson

Institution: Eli Lilly (United States)

Observed institutions: Butler University, Eli Lilly (United States)

OpenAlex ID: A5020455010

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

2017 · Vladimir Skljarevski, Tina M. Oakes, et al. · JAMA Neurology · 172

Duloxetine in the Long-Term Treatment of Major Depressive Disorder

2003 · Joel Raskin, David J. Goldstein, et al. · The Journal of Clinical Psychiatry · 111

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

2019 · Peter J Goadsby, David W Dodick, et al. · Journal of Neurology Neurosurgery & Psychiatry · 39

TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

2025 · Stephen Salloway, Andrew Pain, et al. · Alzheimer s & Dementia · 32

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease

2023 · Stephen Salloway, Elly Lee, et al. · BJPsych Open · 20

Decentralized approaches in TRAILBLAZER-ALZ 3 (P7-6.006)

2023 · Roy Yaari, Karen Holdridge, et al. · Neurology · 12

Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

2016 · Susan G. Ball, Margaret B. Ferguson, et al. · The Journal of Clinical Psychiatry · 12

TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months

2023 · Andrew Pain, Margaret B Ferguson, et al. · Alzheimer s & Dementia · 6

Payment Deferred: Strychnine Poisoning in Nicaragua 65 Years Ago

2000 · Margaret B. Ferguson, Michael A. Vance, et al. · Journal of Toxicology Clinical Toxicology · 5

TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease (S26.009)

2023 · Stephen Salloway, Elly Lee, et al. · Neurology · 4

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

2015 · James Martinez, Margaret Ferguson, et al. · Drugs in Context · 3

Evaluation of the CGRP Neutralizing Antibody LY2951742 for the Treatment of Migraine and Osteoarthritis Pain

2017 · Kirk Johnson, Vladimir Skljarevski, et al. · Neuropeptides

Works count: 12

Citation count: 416

H-index: 7

I10-index: 7